BALBAS, MINNA D.,SAWYERS, CHARLES L.,WATSON, PHILIP
申请号：
CA2889765
公开号：
CA2889765A1
申请日:
2013.10.25
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/ or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation.
